EGFRvIII
Invention
EGFRvII is a tool to early detect cancer. The future market of cancer diagnostic is booming and its importance increases as diagnostic testing reduces healthcare expenditures. Cancer diagnostics can be used for screening as well as for verification of treatment strategies. Early stage cancer detection is of crucial importance for successful treatment of cancer. Early stage diagnosis brings cost beneficial treatment and increases survival rates. Current cancer diagnostic tools provide expensive cancer screening programs, while for some cancer types there is no reliable alternative early stage cancer marks available. The EGFRvIII enables detection of cancer in early stage and can be applicable to different cancer types. This new technology is a fast and easy to use in laboratories. The approach has a clear cost benefits compared to established programs allowing better patient treatment.
Applications
In diagnostics of early stages of cancer.
Advantages
- early stage detection of cancer
– applied to various cancer types
– fast and easy to use in laboratories
– advanced patient treatment due to the early diagnostics
Technology
The EGFRvIII relates to the methods for the detection of EGFRvIII. In particular it relates to single step PCR based method for the detection of EGFRvIII in biological samples. EGFRvIII is known to be tumor specific. EGFRvIII is an assay which can detect and quantify EGFRvIII in blood and is of critical importance in the early detection of various cancers, and also in prognosis, monitoring, and response to therapy. In addition, this assay could serve in the selection of cancer patients for novel mutant EGF-directed anticancer therapies, such as a vaccine, antibody-toxin conjugate, or EGFRvIII-specific tyrosine kinase inhibitors.
The invention is filed with the European Patent Office (EP01978103A1), and a PCT (WO28119562A1) applies on the technology giving it a broad IP protection.
Interested in this technology?
Interested investor or partners may contact business development manager Torsten Porwol. Click here for contact information.